A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.

ABSTRACT: Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor response rates to the individual therapies has limited their success. Designing rational combinations of targeted therapy and immunotherapy may overcome these obstacles, but requires assessment in preclinical models with the capacity to respond to both therapeutic classes. Herein, we describe the development and characterization of a novel, immunogenic variant of the Braf^V600ECdkn2a^-/-Pten^-/- YUMM1.1 tumor model that expresses the immunogen, ovalbumin (YOVAL1.1). We demonstrate that, unlike parental tumors, YOVAL1.1 tumors are immunogenic in vivo and can be controlled by immunotherapy. Importantly, YOVAL1.1 tumors are sensitive t

SUBMITTER: Lelliott EJ 

PROVIDER: S-EPMC6361951 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature